The complexity and mutagenicity of viral and bacterial pathogens requires a new flexibility and efficiency in the development of vaccines. BioCopy’s technology helps select vaccine candidates very soon after pathogen identification. In this way, vaccines against new pathogens can be developed much faster and more efficiently.
With our cutting-edge high-throughput microarray technology, we can handle the vast complexity of mutated pathogen variants and translate it into processable data for vaccine development. We map the complexity of pathogens by synthesizing immunogens on a chip and detect the immune response using serum samples directly on the chip.
The BioCopy microfluidics platform with parallel detection of thousands of samples allows for rapid turnover and saves serum specimen. This significantly shortens development time to support early market availability of urgently needed vaccines.
BioCopy’s technology can be applied to influenza or SARS-CoV-2 – prominent examples of high mutation rates leading to escape mutants that can bypass vaccine protection.